New hope for kids with rare swelling disorder
NCT ID NCT06467084
Summary
This study tested the safety and effectiveness of a medication called sebetralstat (KVD900) in children aged 2 to 11 with hereditary angioedema (HAE), a rare genetic condition that causes sudden, severe swelling attacks. The trial involved 36 children and aimed to see how well the drug worked to control and resolve these attacks, as reported by their caregivers. It was an open-label study, meaning everyone knew they were receiving the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
KalVista Investigative Site
Birmingham, Alabama, 35209, United States
-
KalVista Investigative Site
Scottsdale, Arizona, 85251, United States
-
KalVista Investigative Site
San Diego, California, 92123, United States
-
KalVista Investigative Site
Santa Monica, California, 90404, United States
-
KalVista Investigative Site
Evansville, Indiana, 47715, United States
-
KalVista Investigative Site
Wheaton, Maryland, 20902, United States
-
KalVista Investigative Site
St Louis, Missouri, 63141, United States
-
KalVista Investigative Site
Toledo, Ohio, 43560, United States
-
KalVista Investigative Site
Hershey, Pennsylvania, 17011, United States
-
KalVista Investigative Site
Dallas, Texas, 75231, United States
-
KalVista Investigative Site
Edmonton, Alberta, T6G 2B7, Canada
-
KalVista Investigative Site
Lille, 59000, France
-
KalVista Investigative Site
Marseille, 13005, France
-
KalVista Investigative Site
Paris, 75012, France
-
KalVista Investigative Site
Frankfurt am Main, 60590, Germany
-
KalVista Investigative Site
Frankfurt am Main, 60596, Germany
-
KalVista Investigative Site
Haifa, 31048, Israel
-
KalVista Investigative Site
Petah Tikva, 4920235, Israel
-
KalVista Investigative Site
Tel Aviv, 6423906, Israel
-
KalVista Investigative Site
Milan, 20097, Italy
-
KalVista Investigative Site
Padua, 35128, Italy
-
KalVista Investigative Site
Rome, 00133, Italy
-
KalVista Investigative Site
Kawagoe, 350-8550, Japan
-
KalVista Investigative Site
Tokyo, 113-8431, Japan
Conditions
Explore the condition pages connected to this study.